The course of Disease Activity, infliximab serum concentrations and anti-infliximab antibody concentrations measured, between two standard infliximab infusion time- periods, in patients with rheumatoid arthritis.

The course of Disease Activity, infliximab serum concentrations and anti-infliximab antibody concentrations measured, between two standard infliximab infusion time- periods, in patients with rheumatoid arthritis. - Disease activity and (anti)infliximablevels between two infliximabdoses

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31619

Enrollment

Registered

2008-05-20

Start date

2008-03-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients who had fulfilled the 1987 ACR criteria and had started infliximab therapy for at least 3 months

Exclusion criteria

Exclusion criteria: There are no exclusioncriteria for this study other than the regulatory contraindications

Design outcomes

Primary

Measure	Time frame
DAS28	—

Secondary

Measure	Time frame
infliximab serum levels and anti-inflximab serum levels	—

Countries

Netherlands

Outcome results